Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2/3 1

Status

Active not recruiting 3Completed 2Recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 236CNS 17Tumor-Agnostic 6Gastrointestinal 6Other solid neoplasm 5Head & Neck 4Gynecologic 3Genitourinary 3Breast 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Other 1Endocrine 1

Conditions

Neoplasms 4Carcinoma 2Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Capecitabine 47Radiotherapy 46Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
osimertinib × Tumor-Agnostic × Clear all
NCT07005102 2026-05-22

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

Phase 2/3 Recruiting
854 enrolled
Tumor-Agnostic

Neoplasms

NCT05261399 2026-04-06

SAFFRON

AstraZeneca

Phase 3 Active not recruiting
345 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

AstraZeneca

Phase 3 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasms

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
237 enrolled
Tumor-Agnostic

Neoplasms

NCT02529995 2020-02-11

AURAChinaPK

AstraZeneca

Phase 1 Completed
31 enrolled 22 charts
Tumor-Agnostic

Carcinoma

NCT02491944 2016-10-13

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

AstraZeneca

Phase 1 Completed
27 enrolled 21 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡